Discussions with / outreach to (and/or preparation for such outreach) Congressional offices and HHS officials re: potential avenues to increase GLP-1 access as a method of substance use disorder (SUD) treatment and other potential strategies for increasing innovation and the development of improved addiction medicines; FDA reforms including modernized endpoints for SUD (including support letters and FY26 appropriations language: Ag-FDA S.2256, H.R. 4121); potential legislation to create a SUD PRV to increase development of and access to new SUD medicines. Support for the FDA Commissioners announced national PRV.
2025 · 2nd Quarter (Apr 1 - June 30)
CENTER FOR ADDICTION SCIENCE, POLICY, AND RESEARCH
Filed by TENAGRITY SOLUTIONS, LLC.
Open official filingSource-reported fields
Filing overview
- Type
- 2nd Quarter - Report
- Posted
- Jul 21, 2025
- Income
- $20,000.00
- Expenses
- Not reported
- Registrant
- TENAGRITY SOLUTIONS, LLC
- Filing UUID
- 65611601-7425-4e68-9242-f0fab220bd61
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Discussions with / outreach to (and/or preparation for such outreach) Congressional offices and HHS officials re: potential avenues to increase GLP-1 access (for veterans and others) as a method of substance use disorder (SUD) treatment and other potential strategies for increasing innovation and the development of improved addiction medicines; FDA reforms including modernized endpoints for SUD (including support letters and FY26 appropriations language, Ag-FDA S.2256, H.R. 4121); potential legislation to create a SUD PRV to increase development of and access to new SUD medicines. Support for the FDA Commissioners announced national PRV.
Discussions with / outreach to (and/or preparation for such outreach) Congressional offices and HHS officials re: potential avenues to increase GLP-1 access as a method of substance use disorder (SUD) treatment and other potential strategies for increasing innovation and the development of improved addiction medicines; FDA reforms including modernized endpoints for SUD (including support letters and FY26 appropriations language, Ag-FDA S.2256, H.R. 4121); potential legislation to create a SUD PRV to increase development of and access to new SUD medicines. Support for the FDA Commissioners announced national PRV.
Discussions with / outreach to (and/or preparation for such outreach) Congressional offices and HHS officials re: potential avenues to increase GLP-1 access as a method of substance use disorder (SUD) treatment and other potential strategies for increasing innovation and the development of improved addiction medicines; FDA reforms including modernized endpoints for SUD (including support letters and FY26 appropriations language: Ag-FDA S.2256, H.R. 4121); potential legislation to create a SUD PRV to increase development of and access to new SUD medicines. Support for the FDA Commissioners announced national PRV.
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.